ASCO And The CAP Issue Joint Guideline To Improve Hormone Receptor Testing For Patients With Breast Cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, April 20, 2010

ASCO And The CAP Issue Joint Guideline To Improve Hormone Receptor Testing For Patients With Breast Cancer



""There is clearly a need to accurately identify breast cancer subtypes as ER and/or PgR-positive to help us identify those patients most likely to benefit from endocrine therapy and minimize the risk of potentially denying effective and life-saving therapy to patients incorrectly labeled as having ER/PgR-negative invasive disease, while allowing patients with true ER/PgR-negative disease to be considered for other therapies." said Antonio C. Wolff, MD, FACP, co-chair of the ASCO/CAP Hormone Receptor Testing in Breast Cancer Panel and associate professor of oncology at the Johns Hopkins Kimmel Comprehensive Cancer Center. The guideline recommends the following:" (see article for further information)

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.